CEBPZ and acute myeloid leukemia: These include the detection of aberrant immunophenotypes by multiparameter flow cytometric (MFC) analyses and the detection of fusion transcripts by quantitative polymerase chain reaction (qRT-PCR) in core-binding factor AML (CBF), as well as NPM1 mutations in NPM1-mutated AML.